PineTree Therapeutics Raises $23.5M in Series A1 Funding
Summary
PineTree Therapeutics, a Cambridge, MA-based biotech company which specializes in therapies in oncology, immuno-oncology and other diseases, raised $23.5M in Series A1 funding. The company intends to use the funds to advance their oncology and viral diseases platforms. Led by CEO HoJuhn Song, PineTree Therapeutics is a pre-clinical stage biotech company that has developed the TAER-TAB™ and ViTRAP™ technologies and is building a broad pipeline for hard-to-treat cancers and viral diseases, with an initial focus on oncology.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected